SYMFI Drug Patent Profile
✉ Email this page to a colleague
When do Symfi patents expire, and when can generic versions of Symfi launch?
Symfi is a drug marketed by Mylan Labs Ltd and Mylan and is included in two NDAs.
The generic ingredient in SYMFI is efavirenz; lamivudine; tenofovir disoproxil fumarate. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the efavirenz; lamivudine; tenofovir disoproxil fumarate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SYMFI?
- What are the global sales for SYMFI?
- What is Average Wholesale Price for SYMFI?
Summary for SYMFI
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for SYMFI |
| What excipients (inactive ingredients) are in SYMFI? | SYMFI excipients list |
| DailyMed Link: | SYMFI at DailyMed |
Pharmacology for SYMFI
US Patents and Regulatory Information for SYMFI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | SYMFI | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 022142-001 | Mar 22, 2018 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | SYMFI LO | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 208255-001 | Feb 5, 2018 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
